STOCK TITAN
  1. Home
  2. News
  3. OPTHF

Optimi Health Corp - OPTHF STOCK NEWS

Welcome to our dedicated news page for Optimi Health (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Optimi Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Optimi Health's position in the market.

News
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
Rhea-AI Summary
Optimi Health Corp. has been granted an amendment to its Health Canada Controlled Drugs and Substances Licence, allowing substantial increases in the quantities of MDMA, MDA, and 2CB. This strategic licensing plan positions the company as an industry-leading psychedelics drug manufacturer, preparing for potential approval of MDMA by the U.S. Food and Drug Administration in 2024. The company's 2024 strategic licensing plan includes approvals for a Drug Master File (DMF) and Drug Establishment Licence (DEL) to ensure regulatory compliance and transparency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.62%
Tags
none
-
News
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
Rhea-AI Summary
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) proudly announces the granting of its Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone ('MDP2P') by Health Canada, allowing the company to import MDP2P for formulating and verifying MDMA drug candidates. This achievement positions Optimi to produce MDMA at reduced costs, aligning with market demand and the recent NDA submission by MAPS PBC to the FDA. The successful encapsulation of MDMA into 40mg and 60mg dosage formats further solidifies Optimi's strategic position as a premier provider of encapsulated MDMA in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.08%
Tags
none
-
News
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
Rhea-AI Summary
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) announced a supply agreement with Sunshine Earth Labs Ltd., a fellow biosciences company, to provide GMP quality-controlled substances for medicinal and research purposes. The partnership leverages the strengths of two reputable companies in the psychedelics industry, reinforcing British Columbia's standing as a hub for innovative advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
News
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
Rhea-AI Summary
Optimi Health Corp. (OPTI) has successfully harvested eight new natural Psilocybin genetics, solidifying its position as a leading psychedelic research and formulation company. The company is advancing its full spectrum, GMP extract quality program and has confirmed the product's potency and quality attributes for the duration of clinical trials. Optimi is also making GMP Psilocybin API available for encapsulation into standardized dosages or sale to other groups, expanding its reach and impact within the psychedelic research community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.74%
Tags
none
-
News
Optimi Health Resolves Dispute
Rhea-AI Summary
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) announces the successful resolution of a dispute related to a supply agreement, emphasizing commitment to positive relationships and business integrity in the psychedelics sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer
Rhea-AI Summary
Optimi Health Corp. appoints Dr. Preston A. Chase as Chief Science Officer, bringing extensive experience in R&D and commercialization of innovative products. Dr. Chase will lead the scientific team to advance research capabilities and develop safe, effective psychedelics drug candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
none
News
Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing
Rhea-AI Summary
Optimi Health Corp. has secured a non-dilutive Debt Financing Agreement and General Security Agreement for CAD$1,000,000. The loan is secured against the company's assets and will bear interest at a rate of 7.5% per annum. The loan is repayable on April 30, 2025, and the company has the option to repay it earlier with a prepayment fee. As part of the agreement, the company has granted 100,000 common share purchase warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
Rhea-AI Summary
Optimi Health Corp. sees positive outcomes from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial for PTSD treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
clinical trial
-
News
Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program
Rhea-AI Summary
Optimi Health Corp. receives approval from Health Canada to supply Canada's Special Access Program with psychedelic substances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none
News
Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing
Rhea-AI Summary
Optimi Health Corp. secures CAD$1,000,000 non-dilutive Debt Financing Agreement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.14%
Tags
none
Stock OPTHF logo
Optimi Health Corp

OTC:OPTHF

OPTHF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

OPTHF Stock Data

16.30M
72.33M
17.55%
0.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Vancouver